Aytu BioScience EPS misses by $1.08, misses on revenue
- BySeeking Alpha-
Aytu BioScience (NASDAQ:AYTU): Q3 GAAP EPS of -$1.41 misses by $1.08.Revenue of $13.48M (+64.4% Y/Y) misses by $0.56M.Shares -5.9%.Press Release
Symbol | Exchange | Currency |
|---|
Aytu BioScience (NASDAQ:AYTU): Q3 GAAP EPS of -$1.41 misses by $1.08.Revenue of $13.48M (+64.4% Y/Y) misses by $0.56M.Shares -5.9%.Press Release
Here's a roundup of top developments in ...Full story available on Benzinga.com
Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU)+14%; Translate Bio (TBIO) -32%, ContraFect (CFRX) -13%
bluebird Inc. BLUE announced new data from ongoing phase III studies onits investigational betibeglogene autotemcel (formerly LentiGlobin for β-thalassemia gene therapy). The...
Aytu BioScience, Inc. (NASDAQ:AYTU) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 145.85 | 146.43 | 143.70 | +2.42 | +1.69% | 75.29M | NASDAQ | |||
| 343.21 | 349.84 | 340.69 | -14.27 | -3.99% | 42.98M | NASDAQ | |||
| 2,805.70 | 2,817.70 | 2,771.00 | +25.0 | +0.90% | 1.24M | NASDAQ | |||
| 5.45 | 5.63 | 5.45 | -0.040 | -0.73% | 14.28M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 43.95 | 44.39 | 43.83 | +0.03 | +0.07% | 20.16M | NYSE | |||
| 18.45 | 18.81 | 18.41 | -0.04 | -0.22% | 16.99M | NYSE | |||
| 9.95 | 11.06 | 9.94 | +2.45 | +32.67% | 330.71K | OTC Markets | |||
| 0.4671 | 0.00 | 0.00 | +0.0166 | +3.68% | 1.93M | NYSE | |||
| 207.81 | 210.55 | 202.57 | +3.10 | +1.51% | 508.38K | NYSE | |||
| 38.50 | 38.74 | 38.07 | +0.40 | +1.05% | 31.82K | NASDAQ | |||
| 10.54 | 10.72 | 10.34 | +0.28 | +2.73% | 3.44M | NASDAQ | |||
| 145.17 | 146.43 | 143.72 | +2.87 | +2.02% | 1.38M | NYSE | |||
| 1.37 | 1.51 | 1.37 | -0.0400 | -2.84% | 21.42M | NYSE | |||
| 12.29 | 12.74 | 12.28 | +0.09 | +0.74% | 4.55M | NYSE |
Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.